EuKedos S.p.A (EUK) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of EuKedos S.p.A €0.53, price €0.48, upside +11.3%, quality 38 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch EuKedos S.p.A for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range €0.4760 – €3.19 · fair‑value band €0.5300 – €1.82 · the €0.4760 price screens below the €0.5300 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Follow EuKedos S.p.A in your weekly email
Every Wednesday you see whether EuKedos S.p.A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
EuKedos S.p.A. operates in the managed-care sector in Italy. It manages nursing homes. The company also offers residential and day care to independent and dependent elderly people, and disabled adults, as well as people with mild, moderate, and severe cognitive impairment and patients with psychiatric conditions.
Show more
EuKedos S.p.A. operates in the managed-care sector in Italy. It manages nursing homes. The company also offers residential and day care to independent and dependent elderly people, and disabled adults, as well as people with mild, moderate, and severe cognitive impairment and patients with psychiatric conditions. In addition, it manages healthcare residences. The company is based in Florence, Italy. EuKedos S.p.A. operates as a subsidiary of La Villa S.p.A.
Stock analysis
EuKedos S.p.A (EUK) currently trades at €0.4760, while our model-based Fair Value estimate is €0.5300, implying the stock looks roughly 10.2% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of €1.71 per share, and 9 of the 10 models we run sit above the €0.4760 price.
Bear case: the DCF Models group reads lowest at €0.6400, and 1 of the 10 models stay below the price. Evidence for this calculation is low.
Scenario range: €0.5300 (bear) to €1.82 (bull), the price of €0.4760 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
EuKedos S.p.A reported revenue of €52.9M in FY2025 versus €45.2M in FY2021, a compound +4.0%/yr. Reported net income was −€749K in FY2025.
Key figures
Market cap €10.8M · P/S ratio 0.22 · EPS (TTM) €−0.0300 · Net margin −1.4% · Return on equity −2.5% · Return on assets (EBIT) 2.7% · Operating margin 12.7% · Revenue (TTM) €52.9M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 41% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at 11%, EUK screens richer than that median.
Fair Value models
Bear €0.5300Fair Value €0.5300Bull €1.82
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.35/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+2.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.4%
Start year 2020 (pandemic). Over 10 years: +0.1% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
2.8% (2020) → 10.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+56.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +52.8% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 258 stocks
Beats the industry median on 5/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score38 · Bottom 25%
Fair Value upside+11% · Above median
Profitability
Return on assets2% · Below median
Net margin (TTM)−1% · Bottom 25%
Operating margin (TTM)13% · Above median
Growth and dividend
Revenue growth1% · Below median
Balance sheet
Debt / equity1.84× · Highest 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "EuKedos S.p.A Fair Value". https://www.fairvalue-calculator.com/stock/EUK
Frequently asked questions
Is EuKedos S.p.A (EUK) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of €0.5300 versus a price of €0.4760, about +11% upside (undervalued).
What is the fair value of EUK?
Our model-based fair value for EuKedos S.p.A is €0.5300 (as of Sep 23, 2026), built from audited fundamentals. The current price: €0.4760.
What is the quality score of EUK?
EuKedos S.p.A has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for EuKedos S.p.A (EUK)?
Our model-based price target is the fair value of €0.5300 (as of Sep 23, 2026) from 12 valuation models. Cautious scenario €0.5300, optimistic scenario €1.82. It is a calculation from audited fundamentals, not an analyst target.
What is the EuKedos S.p.A stock forecast for 2026?
Our models put fair value at €0.5300, about +11% upside versus a price of €0.4760 (undervalued). Cautious scenario €0.5300, optimistic scenario €1.82. The calculation is refreshed regularly with new filings.
What is the revenue of EuKedos S.p.A (EUK)?
EuKedos S.p.A reported trailing-twelve-month revenue of about €52.9M (latest available figure, as of Sep 23, 2026).
What growth is priced into EuKedos S.p.A (EUK)?
For today's price to be fair in a discounted-cash-flow model, EuKedos S.p.A would have to grow free cash flow by +56.1 % per year for five years (discount rate 10.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +2.4 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of EUK use?
Our models discount EuKedos S.p.A at 10.5 %: a base by market capitalisation (nano), damped by beta 0.23, country premium for Italy. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For EuKedos S.p.A that is +56.1 % per year a year over ten years, using the same discount rate (10.5 %) and the same formula as our fair value.
How much growth has EuKedos S.p.A (EUK) delivered so far?
Over the past 5 years revenue at EuKedos S.p.A grew +2.4 % a year. The price currently implies +56.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of EuKedos S.p.A (EUK) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into EuKedos S.p.A (+56.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of EuKedos S.p.A (EUK)?
The free-cash-flow yield on the price is 4.03 %: that much free cash flow EuKedos S.p.A produces per unit of market value. When it exceeds the discount rate of our models (10.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of EuKedos S.p.A (EUK)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For EuKedos S.p.A it is €0.5300 per share (as of Sep 23, 2026), against a price of €0.4760. It is the blended result of 12 valuation models (cash flow, earnings, asset, dividend).
Is EuKedos S.p.A stock overvalued or undervalued in 2026?
As of Sep 23, 2026, EUK trades below its calculated fair value: price €0.4760, fair value €0.5300, a gap of about +11% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EUK?
No. The price is what the market pays today (€0.4760); the fair value is what the company's own numbers justify (€0.5300). For EuKedos S.p.A the two are €0.0540 per share apart. That gap is exactly why we show both numbers side by side.
How much is EuKedos S.p.A worth?
The market values EuKedos S.p.A at about €10.8M (market capitalisation, as of Sep 23, 2026). Per share that is €0.4760; our models calculate a fair value of €0.5300 per share.
What do the bullish and bearish scenarios say about EUK?
Our models span a range for EuKedos S.p.A: cautious scenario €0.5300, base €0.5300, optimistic €1.82 per share (as of Sep 23, 2026, price €0.4760). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of EuKedos S.p.A (EUK)?
Balance-sheet figures for EuKedos S.p.A (as of Sep 23, 2026): return on equity −2.5%, debt of 1.84 per unit of equity. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is EUK from its 52-week high?
EuKedos S.p.A trades at €0.4760, about 41% below its 52-week high of €0.8100 and at the low of €0.4760 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of €0.5300 is for.
Which stocks are comparable to EuKedos S.p.A?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, IHH Healthcare Berhad, an investment holding company,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is EuKedos S.p.A stock attractive at the current price?
The data as of Sep 23, 2026: price €0.4760, calculated fair value €0.5300 (+11%), Quality Score 38/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EUK calculated?
We run EuKedos S.p.A through 12 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €0.5300, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. EuKedos S.p.A currently trades 11 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of EuKedos S.p.A (EUK)?
The closing price on Sep 24, 2026 was €0.4760. Our model-based fair value is €0.5300, about +11% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with EuKedos S.p.A right now?
The price is below even our cautious bear case (€0.5300). The market is more pessimistic than our downside scenario. The model range is unusually wide (€0.5300 to €1.82). The outcome hinges heavily on assumptions, so read the point estimate with caution. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of EuKedos S.p.A
How large is the market capitalisation of EuKedos S.p.A (EUK)?
The market capitalisation of EuKedos S.p.A is €10.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of EuKedos S.p.A (EUK)?
The price-to-sales ratio of EuKedos S.p.A is 0.22 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of EuKedos S.p.A (EUK)?
Earnings per share at EuKedos S.p.A are €−0.0300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of EuKedos S.p.A (EUK)?
The net margin of EuKedos S.p.A is −1.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of EuKedos S.p.A (EUK)?
The return on equity (ROE) of EuKedos S.p.A is −2.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of EuKedos S.p.A (EUK)?
On an EBIT basis the return on assets of EuKedos S.p.A is 2.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of EuKedos S.p.A (EUK)?
The operating margin of EuKedos S.p.A is 12.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at EuKedos S.p.A (EUK)?
Revenue at EuKedos S.p.A is growing +1.1% versus a year earlier (3y avg +4.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at EuKedos S.p.A (EUK)?
Earnings per share at EuKedos S.p.A are growing +20.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does EuKedos S.p.A (EUK) carry?
The net debt of EuKedos S.p.A is €68.3M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch EuKedos S.p.A in the live analysis
One click puts EuKedos S.p.A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
